# 510(k) Summary

1. Euro-Diagnostica AB, Lundavägen 151, SE-212 24 Malmo, Sweden Contact person: Ms. Annika Andersson Telephone: $+ 4 6$ 40 53 76 04 Fax: $+ 4 6$ 40 43 22 88 Date of preparation: June 5, 2009 Revised: November 5, 2009

II.Device/Trade name: Immunoscan CCPlus® Common name: Anti-CCP test Governing regulation: 21 CFR 866.5775 Device classification: Class 11 Classification panel: Immunology Product code: NHX

III. Description of Device: The Immunoscan ${ \mathsf { C C P } } | | { \mathsf { S } } ^ { \otimes }$ test kit is a modification of the Immunoscan RA anti-CCP Test kit, K052133. It is an enzyme-linked immunosorbent assay (ELISA) for qualitative and semi-quantitative determination of IgG antibodies to Cyclic Citrullinated Peptides (CCP) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of Rheumatoid Arthritis (RA), in conjunction with other laboratory and clinical findings. The analysis should be performed by trained laboratory professionals. "For in vitro diagnostic use".

The wells are coated with Cyclic Citrullinated Peptides. During the first incubation, specific antibodies in diluted serum, will bind to the antigen coating.

The wells are then washed to remove unbound antibodies and other components. A conjugate of alkaline phosphatase labelled antibodies to human IgG binds to the antibodies in the wells in this second incubation.

After a further washing step, detection of specific antibodies is obtained by incubation with substrate solution. The amount of bound antibodies correlates to the colour intensity and is measured in terms of absorbance (optical density. (OD)). The absorbance is then calculated against a calibrator curve and the results are given in arbitrary units.

IV. Legally marketed device to which equivalence is claimed: Immunoscan RA anti-CCP Test kit, K052133.

V. Intended use of the device: The intended use of the modified device has not changed. The Immunoscan CCPlus® test kit is an enzyme-linked immunosorbent assay (ELISA) for qualitative and semi-quantitative determination of IgG antibodies to Cyclic Citrullinated Peptides (CCP) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of Rheumatoid Arthritis (RA), in conjunction with other laboratory and clinical findings. The analysis should be performed by trained laboratory professionals. "For in vitro diagnostic use".

VI. Comparison of technological characteristics:

Table 1. Similarities and differences between Immunoscan CCPlus® and Predicate Device, Immunoscan RA anti CCP Test kit, K052133   
Similarities   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Modified DeviceImmunoscan CCPlus</td><td rowspan=1 colspan=1>Predicate DeviceImmunoscan RAanti-CCP</td></tr><tr><td rowspan=1 colspan=1>Intended use</td><td rowspan=1 colspan=1>The results of the assayare to be used as an aidto the diagnosis ofRheumatoid Arthritis(RA), in conjunction withother laboratory andclinical findings.</td><td rowspan=1 colspan=1>The results of the assayare to be used as an aidto the diagnosis ofRheumatoid Arthritis(RA), in conjunction withother laboratory andclinical findings.</td></tr><tr><td rowspan=1 colspan=1>Intended user</td><td rowspan=1 colspan=1>For use by health careprofessionals</td><td rowspan=1 colspan=1>For use by health careprofessionals</td></tr><tr><td rowspan=1 colspan=1>Method</td><td rowspan=1 colspan=1>ELISA</td><td rowspan=1 colspan=1>ELISA</td></tr><tr><td rowspan=1 colspan=1>Type of test</td><td rowspan=1 colspan=1>Qualitative and semi-quantitative</td><td rowspan=1 colspan=1>Qualitative and semi-quantitative</td></tr><tr><td rowspan=1 colspan=1>Analyte measured</td><td rowspan=1 colspan=1>Anti-CCP</td><td rowspan=1 colspan=1>Anti-CCP</td></tr><tr><td rowspan=1 colspan=1>Coated antigen</td><td rowspan=1 colspan=1>Synthetic CCP</td><td rowspan=1 colspan=1>Synthetic CCP</td></tr><tr><td rowspan=1 colspan=1>Conjugate</td><td rowspan=1 colspan=1>Anti-human IgG</td><td rowspan=1 colspan=1>Anti-human IgG</td></tr><tr><td rowspan=1 colspan=1>Substrate</td><td rowspan=1 colspan=1>TMB (3, 3&#x27;, 5, 5&#x27;-tetramethylbenzidin)</td><td rowspan=1 colspan=1>TMB (3, 3&#x27;, 5, 5&#x27;-tetramethylbenzidin)</td></tr><tr><td rowspan=1 colspan=1>Wavelength</td><td rowspan=1 colspan=1>450 nm</td><td rowspan=1 colspan=1>450 nm</td></tr><tr><td rowspan=1 colspan=1>Incubation time</td><td rowspan=1 colspan=1>60 min + 30 min + 30 min</td><td rowspan=1 colspan=1>60 min + 30 min + 30 min</td></tr><tr><td rowspan=1 colspan=1>Cut-off</td><td rowspan=1 colspan=1>≥25 U/mL</td><td rowspan=1 colspan=1>≥25 U/mL</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Serum</td><td rowspan=1 colspan=1>Serum</td></tr><tr><td rowspan=1 colspan=1>Sample preparation</td><td rowspan=1 colspan=1>Dilute 1:50</td><td rowspan=1 colspan=1>Dilute 1:50</td></tr><tr><td rowspan=1 colspan=1>Microtitre plate</td><td rowspan=1 colspan=1>Material: PolystyreneSurface: MaxiSorp</td><td rowspan=1 colspan=1>Material: PolystyreneSurface: MaxiSorp</td></tr></table>

Differences   

<table><tr><td rowspan=1 colspan=1>Item</td><td rowspan=1 colspan=1>Modified DeviceImmunoscan CCPlus®</td><td rowspan=1 colspan=1>Predicate DeviceImmunoscan RAanti-CCP</td></tr><tr><td rowspan=1 colspan=1>Microtiter plate</td><td rowspan=1 colspan=1>96 individual wells plateNote: The material andsurface of the microtitreplate are the same</td><td rowspan=1 colspan=1>8 strips x 12 wells plateNote: The material andsurface of the microtitreplate are the same</td></tr><tr><td rowspan=1 colspan=1>Calibrator curve</td><td rowspan=1 colspan=1>25 U/mL, 50 U/mL,200 U/mL, 800 U/mL,3200 U/mLNote: The same material isused to produce thecalibrator</td><td rowspan=1 colspan=1>25 U/mL, 50 U/mL,200 U/mL, 800 U/mL,1600 U/mLNote: The same material isused to produce thecalibrator</td></tr></table>

ViI. Summary of performance: The modified device, Immunoscan CCPlus, is substantially equivalent to the Immunoscan RA anti-CCP Test kit. Equivalence is demonstrated by the following comparative results.

Table 2. Percent agreement of the Immunoscan ${ \mathsf { C C P I u s } } ^ { \otimes }$ compared to the Immunoscan RA anti-CCP Test kit. A total of 628 frozen retrospective sera were assayed. 368 were obtained from RA patients and 260 samples were from apparently healthy blood donors.

<table><tr><td rowspan="3">Immunoscan CCPIUus</td><td rowspan="2">N = 628</td><td colspan="2">Predicate device Immunoscan RA anti-CCP</td></tr><tr><td>Positive</td><td>Negative</td></tr><tr><td>Positive</td><td>275</td><td>5</td></tr><tr><td></td><td>Negative</td><td>2</td><td>346</td></tr></table>

Positive Percent Agreement: $2 7 5 / 2 7 7 = 9 9 . 3 \%$ EY $9 5 \% 0 C l = 9 7 . 4 - 9 9 . 9 \%$ Negative Percent Agreement: 346/351 = 98.6% 95% CI = 96.7 - 99.5% Overall Percent Agreement: 621/628 = 98.9% E $9 5 \% 0 0 \% = 9 7 . 7 - 9 9 . 6 \%$

The $9 5 \%$ confidence interval (Cl) was calculated using the exact method.

Table 3. Clinical sensitivity and specificity. A total of 1180 frozen retrospective sera with clinical characterisation were assayed. The following table summarizes the results.   

<table><tr><td rowspan=2 colspan=1>Patients with clinicallydefined RA</td><td rowspan=1 colspan=1>n</td><td rowspan=1 colspan=1>negative</td><td rowspan=1 colspan=1>positive</td><td rowspan=1 colspan=1>Sensitivity</td></tr><tr><td rowspan=1 colspan=1>399</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>309</td><td rowspan=1 colspan=1>77.4%</td></tr></table>

Clinical sensitivity RA $3 0 9 / 3 9 9 = 7 7 . 4 \%$ $9 5 \% 0 C 1 = 7 3 . 3 - 8 1 . 5 \%$

Clinical specificity for the Immunoscan CCPlus® for non-RA diseased patients and asymptomatic individuals (healthy blood donors).

<table><tr><td rowspan=1 colspan=1>Control andDisease groups</td><td rowspan=1 colspan=1>Totalnumber</td><td rowspan=1 colspan=1>Negative&lt; 25 U/mL</td><td rowspan=1 colspan=1>Positive≥ 25 U/mL</td></tr><tr><td rowspan=1 colspan=1>Blood donors</td><td rowspan=1 colspan=1>260</td><td rowspan=1 colspan=1>257</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>RA</td><td rowspan=1 colspan=1>399</td><td rowspan=1 colspan=1>90</td><td rowspan=1 colspan=1>309</td></tr><tr><td rowspan=1 colspan=1>WG</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>18</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>MP</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>SLE</td><td rowspan=1 colspan=1>66</td><td rowspan=1 colspan=1>64</td><td rowspan=1 colspan=1>2</td></tr><tr><td rowspan=1 colspan=1>Sjogren&#x27;s syndrome</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>13</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>IBD</td><td rowspan=1 colspan=1>98</td><td rowspan=1 colspan=1>95</td><td rowspan=1 colspan=1>3</td></tr><tr><td rowspan=1 colspan=1>Osteoarthritis</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>21</td><td rowspan=1 colspan=1>.0</td></tr><tr><td rowspan=1 colspan=1>Thyroiditis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Epstein Barr Virus</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Parvovirus</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Mycoplasma</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Toxoplasma</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Tuberculosis</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Yersinia</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Salmonella</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Chlamydia</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Malaria</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Borrelia</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>9</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Syphilis</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Infectious endocarditis</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Legionella</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>AST</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Schistomiasis</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>4</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Rubella</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>5</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Chaga&#x27;s syndrome</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>Scleroderma</td><td rowspan=1 colspan=1>17</td><td rowspan=1 colspan=1>16</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Multiple Sclerosis</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>IDDM</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>PM/DM</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>0</td></tr><tr><td rowspan=1 colspan=1>MCTD</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>19</td><td rowspan=1 colspan=1>1</td></tr><tr><td rowspan=1 colspan=1>Routine samples</td><td rowspan=1 colspan=1>80</td><td rowspan=1 colspan=1>78</td><td rowspan=1 colspan=1>2</td></tr></table>

RA $\lneq$ rheumatoid arthritis WG $\Bumpeq$ Wegener's granulomatosis MP $\eqcirc$ microscopic polyangiitis SLE $\mathbf { \eqcirc }$ systemic lupus erythematosus PM/DM $\equiv$ Polymyositis/Dermatomyositis IBD $=$ inflammatory bowel disease AST anti-Streptolysine test IDDM $=$ insulin dependent diabetes mellitus MCTD $=$ mixed connective tissue disease

Blood donors = 257/260 = 98.8% 95% CI = 96.7 - 99.8% WG = 18/20 = 90.0% 95% Cl = 68.3 - 98.8% MP = 20/20 = 100% 95% CI = 83.2 - 100% SLE = 64/66 = 97.0 % 95% Cl = 89.5 - 99.6% Sjogren's = 13/13 = 100 % 95% CI = 75.3 - 100% IBD = 95/98 = 96.9% 95% CI = 91.3 - 99.4% Osteoarthritis = 21/21 = 100% 95% Cl = 83.9 - 100% Thyroiditis = 20/20 = 100% 95% CI = 83.2 - 100% Infectious Disease = 85/86 = 98.8% 95% CI = 93.7 - 100% Scleroderma = 16/17 = 94.1% 95% CI = 71.3 - 99.8% Multiple Sclerosis = 20/20 = 100% 95% CI = 83.2 - 100% IDDM = 20/20 = 100% 95% CI = 83.2 - 100% PM/DM = 20/20 = 100% 95% CI = 83.2 - 100% MCTD = 19/20 = 95.0% 95% CI = 75.1 - 99.9% Routine samples = 78/80 = 97.5 % 95% Cl = 91.3 - 99.7 %

The $9 5 \%$ confidence interval (Cl) was calculated using the exact method.

Table 4. Intra-assay precision was determined by testing six different samples eight times each.   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>High</td><td rowspan=1 colspan=2>High</td><td rowspan=1 colspan=2>High</td></tr><tr><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td></tr><tr><td rowspan=1 colspan=1>Mean.</td><td rowspan=1 colspan=1>2672</td><td rowspan=1 colspan=1>1.421</td><td rowspan=1 colspan=1>2685</td><td rowspan=1 colspan=1>1.432</td><td rowspan=1 colspan=1>1150</td><td rowspan=1 colspan=1>1.664</td></tr><tr><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>138</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>205</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>55.3</td><td rowspan=1 colspan=1>0.02</td></tr><tr><td rowspan=1 colspan=1>% C.V.</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>7.6</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>4.8</td><td rowspan=1 colspan=1>0.9</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>Medium</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=2>Low</td></tr><tr><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>239</td><td rowspan=1 colspan=1>1.014</td><td rowspan=1 colspan=1>56</td><td rowspan=1 colspan=1>0.421</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0.232</td></tr><tr><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>2.3</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.01</td></tr><tr><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>1.0</td><td rowspan=1 colspan=1>0.4</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>2.8</td><td rowspan=1 colspan=1>3.6</td><td rowspan=1 colspan=1>1.3</td></tr></table>

Table 5. Inter-assay precision was determined by testing six .different samples eight times each. Results were obtained for three different runs.   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>High</td><td rowspan=1 colspan=2>High</td><td rowspan=1 colspan=2>High</td></tr><tr><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td></tr><tr><td rowspan=1 colspan=1>Mean.</td><td rowspan=1 colspan=1>2696</td><td rowspan=1 colspan=1>1.426</td><td rowspan=1 colspan=1>2600</td><td rowspan=1 colspan=1>1.422</td><td rowspan=1 colspan=1>1168</td><td rowspan=1 colspan=1>1.706</td></tr><tr><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>328</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>299</td><td rowspan=1 colspan=1>0.01</td><td rowspan=1 colspan=1>101.7</td><td rowspan=1 colspan=1>0.07</td></tr><tr><td rowspan=1 colspan=1>% C.V.</td><td rowspan=1 colspan=1>12.2</td><td rowspan=1 colspan=1>0.7</td><td rowspan=1 colspan=1>11.5</td><td rowspan=1 colspan=1>0.8</td><td rowspan=1 colspan=1>8.7</td><td rowspan=1 colspan=1>3.8</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>Medium</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=2>Low</td></tr><tr><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>242</td><td rowspan=1 colspan=1>1.031</td><td rowspan=1 colspan=1>59</td><td rowspan=1 colspan=1>0.428</td><td rowspan=1 colspan=1>28</td><td rowspan=1 colspan=1>0.232</td></tr><tr><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>5.0</td><td rowspan=1 colspan=1>0.03</td><td rowspan=1 colspan=1>3.1</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>0.5</td><td rowspan=1 colspan=1>0.01</td></tr><tr><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>2.1</td><td rowspan=1 colspan=1>2.5</td><td rowspan=1 colspan=1>5.2</td><td rowspan=1 colspan=1>3.8</td><td rowspan=1 colspan=1>1.8</td><td rowspan=1 colspan=1>0.9</td></tr></table>

Table 6. Lot to lot variation was determined by testing six different samples eight times each. Results were obtained for three different lots.   

<table><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>High</td><td rowspan=1 colspan=2>High</td><td rowspan=1 colspan=2>High</td></tr><tr><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td></tr><tr><td rowspan=1 colspan=1>Mean.</td><td rowspan=1 colspan=1>2896</td><td rowspan=1 colspan=1>1.408</td><td rowspan=1 colspan=1>2870</td><td rowspan=1 colspan=1>1.408</td><td rowspan=1 colspan=1>1530</td><td rowspan=1 colspan=1>1.807</td></tr><tr><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>405</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>335</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>260.4</td><td rowspan=1 colspan=1>0.03</td></tr><tr><td rowspan=1 colspan=1>% C.V.</td><td rowspan=1 colspan=1>14.0</td><td rowspan=1 colspan=1>1.4</td><td rowspan=1 colspan=1>11.7</td><td rowspan=1 colspan=1>1.5</td><td rowspan=1 colspan=1>17.0</td><td rowspan=1 colspan=1>1.6</td></tr><tr><td rowspan=2 colspan=1></td><td rowspan=1 colspan=2>Medium</td><td rowspan=1 colspan=2>Low</td><td rowspan=1 colspan=2>Low</td></tr><tr><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td><td rowspan=1 colspan=1>U/mL</td><td rowspan=1 colspan=1>OD</td></tr><tr><td rowspan=1 colspan=1>Mean</td><td rowspan=1 colspan=1>259</td><td rowspan=1 colspan=1>1.100</td><td rowspan=1 colspan=1>60</td><td rowspan=1 colspan=1>0.462</td><td rowspan=1 colspan=1>62</td><td rowspan=1 colspan=1>0.471</td></tr><tr><td rowspan=1 colspan=1>S.D.</td><td rowspan=1 colspan=1>21.8</td><td rowspan=1 colspan=1>0.04</td><td rowspan=1 colspan=1>4.2</td><td rowspan=1 colspan=1>0.02</td><td rowspan=1 colspan=1>6.6</td><td rowspan=1 colspan=1>0.04</td></tr><tr><td rowspan=1 colspan=1>%C.V.</td><td rowspan=1 colspan=1>8.4</td><td rowspan=1 colspan=1>3.9</td><td rowspan=1 colspan=1>6.9</td><td rowspan=1 colspan=1>4.4</td><td rowspan=1 colspan=1>10.8</td><td rowspan=1 colspan=1>8.2</td></tr></table>

Table 7. Dilution recovery was determined by testing five serial dilutions for three different samples.   

<table><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Dilution</td><td rowspan=1 colspan=1>Mean MeasuredConcentration(U/mL)</td><td rowspan=1 colspan=1>CalculatedConcentration(U/mL)</td><td rowspan=1 colspan=1>Dilution Corrected% Recovery</td></tr><tr><td rowspan=5 colspan=1>−</td><td rowspan=1 colspan=1>1/50</td><td rowspan=1 colspan=1>395</td><td rowspan=1 colspan=1>395</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>1/100</td><td rowspan=1 colspan=1>195</td><td rowspan=1 colspan=1>198</td><td rowspan=1 colspan=1>98</td></tr><tr><td rowspan=1 colspan=1>1/200</td><td rowspan=1 colspan=1>104</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>105</td></tr><tr><td rowspan=1 colspan=1>1/400</td><td rowspan=1 colspan=1>53</td><td rowspan=1 colspan=1>50</td><td rowspan=1 colspan=1>106</td></tr><tr><td rowspan=1 colspan=1>1/800</td><td rowspan=1 colspan=1>26</td><td rowspan=1 colspan=1>25</td><td rowspan=1 colspan=1>104</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Dilution</td><td rowspan=1 colspan=1>Mean MeasuredConcentration(U/mL)</td><td rowspan=1 colspan=1>CalculatedConcentration(U/mL)</td><td rowspan=1 colspan=1>Dilution Corrected% Recovery</td></tr><tr><td rowspan=5 colspan=1>2</td><td rowspan=1 colspan=1>1/50</td><td rowspan=1 colspan=1>921</td><td rowspan=1 colspan=1>921</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>1/100</td><td rowspan=1 colspan=1>486</td><td rowspan=1 colspan=1>461</td><td rowspan=1 colspan=1>105</td></tr><tr><td rowspan=1 colspan=1>1/200</td><td rowspan=1 colspan=1>257</td><td rowspan=1 colspan=1>230</td><td rowspan=1 colspan=1>112</td></tr><tr><td rowspan=1 colspan=1>1/400</td><td rowspan=1 colspan=1>124</td><td rowspan=1 colspan=1>115</td><td rowspan=1 colspan=1>107</td></tr><tr><td rowspan=1 colspan=1>1/800</td><td rowspan=1 colspan=1>63</td><td rowspan=1 colspan=1>58</td><td rowspan=1 colspan=1>109</td></tr><tr><td rowspan=1 colspan=1>Sample</td><td rowspan=1 colspan=1>Dilution</td><td rowspan=1 colspan=1>Mean MeasuredConcentration(U/mL)</td><td rowspan=1 colspan=1>CalculatedConcentration(U/mL)</td><td rowspan=1 colspan=1>Dilution Corrected% Recovery</td></tr><tr><td rowspan=5 colspan=1>3</td><td rowspan=1 colspan=1>1/50</td><td rowspan=1 colspan=1>2962</td><td rowspan=1 colspan=1>2962</td><td rowspan=1 colspan=1>100</td></tr><tr><td rowspan=1 colspan=1>1/100</td><td rowspan=1 colspan=1>1496</td><td rowspan=1 colspan=1>1481</td><td rowspan=1 colspan=1>101</td></tr><tr><td rowspan=1 colspan=1>1/200</td><td rowspan=1 colspan=1>771</td><td rowspan=1 colspan=1>741</td><td rowspan=1 colspan=1>104</td></tr><tr><td rowspan=1 colspan=1>1/400</td><td rowspan=1 colspan=1>349</td><td rowspan=1 colspan=1>370</td><td rowspan=1 colspan=1>94</td></tr><tr><td rowspan=1 colspan=1>1/800</td><td rowspan=1 colspan=1>194</td><td rowspan=1 colspan=1>185</td><td rowspan=1 colspan=1>105</td></tr></table>

# Detection Limit

The detection limit of the assay was determined by running the zero standard 14 times on three different lots. The detection limit of $1 . 6 0 / m L$ was calculated by finding the mean plus two standard deviations.

# Interference Study

Three low positive samples were spiked with bilirubin at $0 . 2 m g / m L$ , haemoglobin at $4 0 0 m g / \mathsf { d } !$ , lipid at $1 5 m g / m L$ and rheumatoid factor at 200 IU/mL. The data indicates that the assayed concentrations do not interfere with the anti-CCP results.

Summary performance characteristics:

# Clinical sensitivity

Immunoscan CCPlus® 77.4% Predicate device $7 5 . 1 \%$

Clinical specificity Immunoscan CCPlus Between 94.1% - 100% Predicate device Between 94.1% - 100%

Intra-assay precision Immunoscan CCPlus Anti-CCP: 28 - 2685 U/mL %C.V.: 1.0-7.6 Predicate device Anti CCP: 34 - 1007 U/mL %C.V.: 4.3-12.8

Inter-assay precision Immunoscan CCPlus® Anti-CCP: 28 - 2696 U/mL %C.V.: 2.1-12.2 Predicate device Anti CCP: 33 - 1106 U/mL %C.V.: 6.0-17.7

Lot to lot precision Immunoscan CCPlus Anti-CCP: 60 - 2896 U/mL %C.V.: 6.9-17.0 Predicate device Anti CCP: 29 - 1117 U/mL %C.V.: 3.8-12.2 1

Detection Limit Immunoscan CCPlus® 1.6 U/mL Predicate device 1.6 U/mL

VIII. Conclusion

The modified device Immunoscan CCPlus® is similar in intended use and performance characteristics to the originally cleared, K052133, Immunoscan RA anti-CCp Test kit. The modification does not alter the fundamental scientific technology of the device.

same material and surface of ELISA plate   
same production procedure   
performance characteristics are equal or better compared to predicate device

We trust that the information provided in this 510(k) will support a decision of substantial equivalence to the predicate Immunoscan RA anti-CCP Test kit.

Euro-Diagnostica AB   
c/o Dr. Annika Andersson   
Regulatory Affairs Manager   
Lundavägen 151, SE-212 24 Malmo   
Sweden

Re: k091657 Trade/Device Name: Immunoscan CCPlus® Regulation Number: 21 CFR $\ S 8 6 6 . 5 7 7 5$ EPY Regulation Name: Rheumatoid factor immunological test system Regulatory Class: Class II Product Code: NHX Dated: September 28, 2009 Received: October 1, 2009

Dear Dr. Andersson:

We have reviewed your Section $5 1 0 ( { \sf k } )$ premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device s classied see above)into either class II (Special Contros) or lass II (MA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems

Page 2 - Dr. Annika Andersson

(QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desie speciic advice or your device on our labeling regulation (1 CFR Part 801), please to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Offce of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

manatn Cham

Maria M. Chan, Ph.D.   
Director   
Division of Immunology and Hematology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

Enclosure

# Indications for Use

510(k) Number: k091657

Device Name: Immunoscan CCPlus®

Indication For Use: The Immunoscan CCPlus® test kit is an enzyme-linked immunosorbent assay (ELISA) for qualitative and semi-quantitative determination of IgG antibodies to Cyclic Citrullinated Peptides (CCP) in human sera. The assay is used to detect antibodies in a single serum specimen. The results of the assay are to be used as an aid to the diagnosis of Rheumatoid Arthritis (RA), in conjunction with other laboratory and clinical findings. The analysis should be performed by trained laboratory professionals. "For in vitro diagnostic use".

# Concurrence of CDRH, Office of In Vitro Diagnostic Device Evaluation and Safety (OIVD)

Thama 2m (ba

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety